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1. INTRODUCTION 
 
As the world marches towards more advancement in technology, the incidence of 
newer face of the diseases are also unmasked. This is mainly due to environmental 
factors like gradual depletion of ozone layer, pollution, unhealthy food etc. 
 
 Among the various diseases, carcinoma is the most dreadful disease whose 
incidence is on increase and has become the greatest enemy to mankind. Cancer is 
leading cause of death worldwide and accounted for 7.6 million deaths in 2008. In 
females, among various types of cancer, breast cancer is the most commonly occurring 
cancer which is rare in male. In India, breast cancer is the second most common cancer 
with an estimated 115,251 new diagnoses and 53,592 deaths in 2008.
 (1) 
 
 Many modes of treatments are available for breast cancer, which includes 
surgery, radiation therapy and chemotherapy.  The chemotherapeutic drugs approved by 
FDA for breast cancer are Cyclophosphamide, Methotrexate, 5-fluro uracil, Paclitaxel, 
Docetaxel, Doxorubicin etc.These drugs belongs to different chemical groups, each 
exerting their anti cancer activity with different mechanism of action. Although these 
drugs have remarkable cure rate, many of them have high incidence of adverse effects 
like bone marrow depression, alopecia etc. Although these drugs offer high success rate, 
the amount of adverse effects produced are also high. So there is always a search for 
newer drugs with less adverse effects, but more beneficial effects.
 (2) 
 
 Indigenous systems of medicine like Ayurveda, Siddha and Unani, mainly use 
medicinal plants for treatment of various ailments of the human beings and animals. 
With the development of these systems, the herbal plants are being sought after, both by 
patients and by clinicians in search for cure of diseases. Herbal medicine is a form of 
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complementary and alternative medicine and is becoming increasingly popular in both 
developing and developed countries.
(3) 
 
 WHO has described traditional medicine as one of the surest means to achieve 
total health care coverage of the world’s population. In pursuance of its goal of providing 
accessible and culturally acceptable health care for the global population, WHO has 
encouraged the rational use of traditional plant based medicines by member states and 
has developed technical guidelines for the assessment of herbal medicines.
(4,5) 
 
 The herbal drugs have been used throughout the world and have raised greater 
attention in recent times, because of their diverse nature of curing diseases, safety and 
well tolerated remedies compared to the conventional medicines. More over the herbs 
with natural combinations of constituents as a whole, are naturally occurring remedies 
which have proved to be more effective and safer than conventional medicines.
 (6) 
 
 Trachyspermum ammi is a profusely branched annual herb mainly used as 
digestive aid. From the pharmacological investigation it has been proved to possess anti 
microbial, anti hypertensive, hepatoprotective, anti inflammatory effects etc.
  
 
 In invivo study, anticancer activity is done by inducing tumor in animals by 
various methods. Due to ethical issues, the use of animals is much reduced to investigate 
anticancer activity. Though animal models provide more predictable results, invitro 
evaluation is still preferred.   
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            Invitro methods have an edge over invivo methods since they are,  
 Less time consuming 
 More cost effective 
 Large number of compounds can be tested with small amount of 
sample 
 Easier to manage 
 
Because of these advantages, the invitro methods have been adopted to assess the 
anticancer property of a compound at various research laboratories.
 (7) 
 
As anticancer activity of Trachyspermum ammi is not proved, the present study 
has been taken to investigate invitro anticancer activity of various extracts of 
Trachyspermum ammi using MCF-7 cell lines which is universally used for breast cancer.  
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2. OBJECTIVES OF THE STUDY 
 
 To evaluate Phyto chemical properties of the various extracts of seeds of 
Trachyspermum ammi. 
 To evaluate the IC50 concentration of ethanolic extracts of Trachyspermum ammi. 
 To determine the apoptotic activity of ethanolic extracts of Trachyspermum 
ammi. 
 To determine the gene expression of cancer DNA markers in MCF-7 Cell line 
treated with ethanolic extracts of Trachyspermum ammi. 
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3. REVIEW OF LITERATURE 
 
 Cancer is a term used for diseases in which abnormal cells divide without 
control and are able to invade other tissues. Cancer cells can spread to other parts of the 
body through the blood and lymph systems.
 
These are two types of cancers. 
 
 Benign tumors aren't cancerous. They can often be removed, and, in most cases, 
they do not come back. Cells in benign tumors do not spread to other parts of the 
body. 
 Malignant tumors are cancerous. Cells in these tumors can invade nearby 
tissues and spread to other parts of the body. The spread of cancer from one part 
of the body to another is called as metastasis. 
 
3.1 TYPES OF CANCER 
 Carcinoma - cancer that begins in the skin or in tissues that line or cover 
internal organs. There are a number of subtypes of carcinoma, including 
adenocarcinoma, basal cell carcinoma, squamous cell carcinoma, and transitional 
cell carcinoma. 
 Sarcoma - cancer that begins in bone, cartilage, fat, muscle, blood vessels, or 
other connective or supportive tissue. 
 Leukemia - cancer that starts in blood-forming tissue such as the bone marrow 
and causes large numbers of abnormal blood cells to be produced and enter the 
blood. 
 Lymphoma and myeloma - cancers that begin in the cells of the immune 
system. 
 Central nervous system cancers - cancers that begin in the tissues of the brain 
and spinal cord. 
[8]
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3.2 HISTORY 
The Edwin Smith Papyrus, which is the oldest written description of cancer 
known to exist, describes eight cases of breast tumors or ulcers in Egypt that were treated 
with cauterization. However, the document also states that there is no treatment for 
cancer. The original document, written in 3000 BC, was acquired in 1862 by Edwin 
Smith at Luxor, Egypt. 
 
400 B.C. Hippocrates was the first to use the words "carcinos" and "carcinoma" 
to describe tumors, and hence the term "cancer" was coined. "Cancer" is derived from 
the Greek word "karkinos," or crab, which is thought to reference the appearance of 
blood vessels on tumors resembling a crab's claws reaching out. [9] [10] [11] 
 
168 A.D. Galen: a Roman physician, he believed cancer to be curable in early 
stages, and that advanced tumors should be operated upon either by cutting around the 
affected area or by cauterization.  
 
1761 Giovanni Morgagni: began performing autopsies to relate illness to 
pathological findings,. This helped to set a foundation for the study of cancer.
 [9] [10] [11] 
 
When the modern microscope was invented in the 19th century, it allowed 
scientists to study cancer with the unaided eye and the modern pathologic study of 
cancer was born.
 [12] 
 
The first use of drugs to treat cancer in the early 20
th
 century was Mustard gas, 
but its side effect decreasing WBC count was unacceptable. So, researchers looked for 
other substances and discovered Mustin. Since then, several drugs have been developed 
to treat cancer.
 [13] 
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3.3 What causes cancer? 
Cancer arises from one single cell. The transformation from a normal cell into a 
tumor cell is a multistage process, typically a progression from a pre-cancerous lesion to 
malignant tumors. These changes are the result of the interaction between a person's 
genetic factors and three categories of external agents, including: 
 
 physical carcinogens, such as ultraviolet and ionizing radiation; 
 chemical carcinogens, such as asbestos, components of tobacco smoke, 
aflatoxin (a food contaminant) and arsenic (a drinking water contaminant); 
 biological carcinogens, such as infections from certain viruses, bacteria or 
parasites. 
 
 Ageing is another fundamental factor for the development of cancer. The 
incidence of cancer rises dramatically with age, most likely due to a buildup of risks for 
specific cancers that increase with age. The overall risk accumulation is combined with 
the tendency for cellular repair mechanisms to be less effective as a person grows older.
 
[14] 
 
3.4 BREAST CANCER 
Definition  
 Breast cancer is a malignant neoplasm of breast tissue, either in cells that line the 
ducts that carry milk to the nipple (ductal cancer) and or in cells and or in cells that line 
the lobules that involved in the milk production (lobular cancer).
[15] 
Breast cancer may be 
benign or malignant. Benign tumor is not life threatening and non invasive but, 
malignant tumor is life threatening and invasive.
 [16] 
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Types of breast cancer 
[17] [18] 
 
1. Ductal carcinoma in situ (DCIS) – 
 This is the earliest form of breast cancer. In DCIS, cancer cells are in the ducts of 
the breast, but they haven’t started to spread into the surrounding breast tissue. 
 
2. Lobular carcinoma in situ (LCIS) 
                     In LCIS, there are changes to the cells lining the lobes, which slightly 
increases the risk of developing breast cancer later in life. Most women with LCIS never 
develop breast cancer. 
 
3. Invasive breast cancer – 
 If cancer cells have spread outside the lining of the ducts or lobules into 
surrounding breast tissue, it’s called invasive breast cancer. There are different types of 
invasive breast cancer.  
 
a) Invasive ductal breast cancer  
Invasive ductal breast cancer occurs when cancer cells lining the duct have 
spread into surrounding breast tissue. It’s the most common type of breast 
cancer – 4 out of 5 breast cancers (80%) are this type.  
 
b) Invasive lobular breast cancer  
Invasive lobular breast cancer develops from the cells that line the lobes of 
the breast and can sometimes be difficult to diagnose on a mammogram. 
About 1 in 10 breast cancers (10%) are this type 
 
 
9 
 
 
3.5  RARE TYPES   
 Inflammatory breast cancer, triple negative breast cancer and medullary breast 
cancer are the other types of breast cancers.
 
3.6 SYMPTOMS OF BREAST CANCER 
a) a lump in the breast  
b) a change in the size or shape of the breast  
c) dimpling of the skin or thickening in the breast tissue  
d) a nipple that’s turned in (inverted)  
e) a rash (like eczema) on the nipple  
f) discharge from the nipple  
g) Swelling or a lump in the armpit.  
h) Pain in either of the breast or armpit not related to menstrual cycle. 
i) Pus formation and foul odor 
j) Unusual weight loss. 
 
3.7 RISK FACTORS 
 Age and gender -- Your risk of developing breast cancer increases as you get 
older. Most advanced breast cancer cases are found in women over age 50. Men 
can also get breast cancer. But they are 100 times less likely than women to get 
breast cancer.
[19] [20]
 
 Family history of breast cancer -- You may also have a higher risk of breast 
cancer if you have a close relative who has had breast, uterine, ovarian, or colon 
cancer. About 20 - 30% of women with breast cancer have a family history of the 
disease.
[21]
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 Genes -- Some people have genetic mutations that make them more likely to 
develop breast cancer. The most common gene defects are found in the BRCA1 
and BRCA2 genes. These genes normally produce proteins that protect you from 
cancer. If a parent passes you a defective gene, you have an increased risk of 
breast cancer. Women with one of these defects have upto an 80% chance of 
getting breast cancer sometime during their life.
[22]
 
 Menstrual cycle -- Women who got their periods early (before age 12) or went 
through menopause late (after age 55) have an increased risk of breast cancer.
[23]
 
 
Other risk factors include: 
 Alcohol use -- Drinking more than 1 - 2 glasses of alcohol a day, may increase 
your risk of breast cancer.
[24]
 
 Childbirth -- Women who have never had children or who had them only after 
age 30 have an increased risk of breast cancer. Being pregnant more than once or 
becoming pregnant at an early age reduces your risk of breast cancer.
[22]
 
 DES -- Women who took diethylstilbestrol (DES) to prevent miscarriage may 
have an increased risk of breast cancer after age 40. This drug was given to the 
women in the 1940s - 1960s. 
 Hormone replacement therapy (HRT) -- You have a higher risk of breast 
cancer if you have received hormone replacement therapy with estrogen for 
several years or more.
[22]
 
 Obesity -- Obesity has been linked to breast cancer, although this link is not 
completely understood. The theory is that obese women produce more estrogen. 
This can fuel the development of breast cancer.
[25]
 
 Radiation -- If you received radiation therapy as a child or young adult to treat 
cancer of the chest area, you have a very high risk of developing breast cancer. 
11 
 
The younger you started such radiation and the higher the dose, the higher your 
risk. This is especially true if the radiation was given during breast 
development.
[26]
 
3.8 PATHOPHYSIOLOGY 
 The cells of breast tissue undergo abnormal proliferation and differentiation 
which is due to factors like, predisposing factors (gender, age, and genetics), 
precipitating factors (diet, contraceptives, and immune suppression) and unknown 
etiology. It leads to the following,
[27] 
 Genetic mutation of cellular DNA e.g. p53 (apoptotic protein), BRCA1 & 
BRCA2 (tumor suppressor protein), which leads to activation of oncogenes. 
Inactivation of tumor suppressor gene, which control apoptosis leads to 
proliferation and differentiation of cancer cells in the milk duct and growth of 
malignant tumor. 
 Rapid growth of malignant tumor 
 Change in shape of breast 
 Rapid multiplication of cancer cells, leads to an increase in metabolism in the 
cancer cells .So the normal cells will become deprived of nutrients leading to 
unusual loss of weight and fatigue. 
 Obstruction of the milk duct cause rupture of it, so there is release of 
inflammatory mediators such as bradykinin, prostaglandins cause transient 
vasoconstriction. 
 Compression of blood and lymphatic vessels which leads to decreased blood 
supply to breast tissue causing ischemia followed by necrosis. 
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 Swelling of breast tissue will compress the nerve endings and produce pain and 
accumulation of the fluid in the cells, cellular debris, live and dead lymphocytes 
will form pus followed by tissue decay and foul odor will be produced. 
 Cancer cells begin to spread locally via lymphatic vessels and form tumor in 
axillary lymph nodes and supra clavicular lymph nodes which are immovable, 
hard and painless nodes. 
 
Mutation of BRCA gene: 
 Those individuals inheriting defects in DNA and gene or mutation of genes like 
BRCA1, BRCA2 are having more chances to develop breast cancer.  
 
 BRCA1, it is tumor suppressor gene, which produces a protein, called breast 
cancer type susceptibility protein.  The protein encoded by the BRCA1 gene combines 
with the other tumor suppressors ,  DNA damage sensors and signal transducers to form 
a large multi subunit protein complex known as BRCA1- associated genome surveillance 
complex (BASC). It is found in cells of breast and other tissue, where it helps repair of 
DNA double strand, or induces apoptosis. 
 
BRCA2 is also a tumor suppressors gene, it is involved in the repair of 
chromosomal damage with an important role in the error –free repair of DNA double 
strand breaks 
 
Suppression of apoptotic signals: 
 (a) p53 is a protein, encoded by TP53 gene
[28,29,30]
 and having tumor suppressing 
function. p53 can activate the DNA repair to repair the damaged DNA, if fail to repair 
the damaged DNA, p53 will induce apoptosis. p53 can arrest the cell cycle by holding at 
G1/S phase. It plays major role in apoptosis and inhibition of angiogenesis. In cancer, 
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mutation occurs at DNA binding domain (DBD) so the availability of protein to bind to 
its target DNA sequence is inhibited, and thus prevents transcriptional activation of 
genes.
[31] 
 (b) TNFα, the primary role of TNF is in regulation of immune cells. TNF was 
thought to be produced primarily by macrophages,
[32]
 but it is also produced by broad 
variety of cell types including lymphoid cells, endothelial cells, cardiac myocytes , 
adipose tissue and neurons. TNF, being an endogeneous pyrogen,  is able to induce 
fever, apoptotic cell death, sepsis (through IL1 and IL6 production), inflammation and 
inhibit tumorigenesis and viral replication. Dysregulation of TNF production is 
associated with a variety of human diseases including Alzheimer’s disease, [32] cancer, [33] 
major depression
[34]
 and inflammatory bowel disease.
[35] 
 
 TNF can bind to two receptors such as TNF-R1and TNF-R2. TNF-R1 found in 
most tissues where as TNF-R2 found only in immune cells.
 [37] 
 
Over expression of anti apoptotic gene: 
 Bcl2 (B cell lymphoma 2) is a anti apoptotic gene plays important role in 
regulating apoptosis. The Bcl2 gene is involved in many cancers like melanoma, breast, 
prostate, leukemia and lung carcinoma.  Mutation in Bcl2 gene decreases the propensity 
of the cells for undergoing apoptosis.
[38, 39, 40] 
Bcl-2 plays a major role in cancer and its 
resistance thereby interfering with therapeutic action of chemotherapeutic drugs. High 
expression of anti-apoptotic members like Bcl-2 found in human cancers leads to 
neoplastic cell expansion by interfering with normal cell death mechanism. Decrease in 
expression of Bcl-2 leads to apoptosis. 
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3.9 BREAST CANCER TREATMENT 
  Based upon the tumor size, location, involvement of lymph nodes and 
metastasis, risk and stages of the disease, appropriate treatment will be given.
[41] [42] 
SURGERY: Remove cancerous tissue – 
   Lumpectomy removes the breast lump; 
  Mastectomy removes all or part of the breast and possible nearby structures  
 
RADIATION THERAPY: To destroy cancerous tissue. 
CHEMOTHERAPY: 
 It is systemic therapy, used to either shrink the tumor or to reduce the risk of 
reccurence. 
A. Drugs acting directly on cells 
Alkylating agents  
 Nitrogen mustards: Mecholrethamine, Cyclophosphamide,  
 
Antimetabolites 
 Folate antagonist: Methotrexate  
 Purine antagonist: 6-Mercaptopurine, 6-Thioguanine, Azathioprine, 
Fludarabine. 
 Pyrimidine antagonist: 5-Flurouracil, Cytarabine. 
 Taxanes : Paclitaxel, Docetaxel 
 Antibiotics: Actinomycin D, Doxorubicin, Daunorubicin, 
Mitoxantrone, Bleomcins, Mitomycin C. 
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B. Drugs altering hormonal milieu 
Hormone therapy is prescribed to women with ER-positive breast cancer to block 
certain hormones that fuel cancer growth. 
 Selective estrogen receptor modulators: Tamoxifen, Toremifene. 
 Selective estrogen receptor down regulators: Fulvestrant 
 Aromatase inhibitors: Letrozole, Anastrozole. 
3.10  MECHANISM OF ANTICANCER DRUGS 
Block nucleic acid (DNA, RNA) biosynthesis 
[43] 
 Folic Acid Antagonist: inhibit dihydrofolate reductase (methotrexate) 
 Pyrimidine Antagonist: inhibit thymidylate synthetase (fluorouracil) ; 
inhibit DNA polymerase (cytarabine) 
 
Influence the Structure and Function of DNA  
 Alkylating Agent:  cyclophosphamide 
 Antibiotic: bleomycin and mitomycin C 
 
Interfere Protein Synthesis 
 Antitubulin: Taxanes (paclitaxel and docetaxel) Bind tubulin, destroy 
spindle to produce mitotic arrest  
 
Influence hormone homeostasis 
 These drugs bind to hormone receptors to block the actions of the sex hormones 
which results in inhibition of tumor growth. 
 Selective estrogen receptor modulators: Tamoxifen, Toremifene. 
 Selective estrogen receptor down regulators: Fulvestrant 
 Aromatase inhibitors: Letrozole, Anastrozole 
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3.11 MCF CELL LINES 
MTT ASSAY 
 Vidhya and deveraj et al.(2001) reported the anti prolerave action of eugenol 
treated MCF-7 cell line by MTT assay. The percentage of cell viability was calculated 
based on absorbance read in elisa reader at 570nm.
[44] 
 
Khaghanini et al. (2011) studied the cytotoxicity of aqueous extract of Hibiscus 
sabdariffa against MCF-7 cell line by MTT assay. To determine the IC50 the absorbance 
was taken at 540nm spectrometrically. 
[45] 
 
APOPTOSIS 
 Ahmad bustmam et al. (2009) examined the morphological changes and probable 
mode of cancer death induced in G.umbrosus treated MCF-7 celll line. The changes such 
as memdrane blebs, DNA condensation and fragmentation as sign of apoptosis were 
observed by inverted and fluorescent microscope used acridine orange and propidium 
iodide as staining media. Endonucleosomal fragmentation action in treated cells was 
studied by DNA laderring assay. 
[46] 
 
 Vidhya and deveraj et al. (2001) studied the induction of apoptosis by eugenol in 
human breast cancer cell lines. Used various staining technique for observe apoptosis 
such as giemsa stain for morphological alteration, fluorescence microscopy analysis of 
cells using acridine orange and ethidium bromide and quantification of DNA 
fragments.
[44]
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 Khaghanii et al. (2011) studied the induction of apotosis in Hibiscus sabdariffa 
treated MCF-7 cell lines. The pattern of DNA cleavage as sign of apoptosis was analysed 
by agarose gel electrophoresis method.
 [45] 
 
Expression of cancer DNA markers 
 Ali A Alshawti et al. (2010) reported the expression of mRNA levels of TP53 and 
caspases using reference gene GAPDH in catechin hydrate treated MCF-7 cells by RT-
PCR.
[47] 
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FIGURE-1: Seeds of Trachyspermum ammi 
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3.12 PLANT PROFILE
 [48, 49, 50, 51] 
 
Botanical name        : Trachyspermum ammi 
Synonym                  : Carum copticum 
Family                      : Apiaceae  
Common names 
          Tamil             : Omam 
          English          : Bishop’s weed 
          Hindi             : Ajwain, Jewain  
         Sanskrit         : Yamini, Yaminiki 
Parts used              : Seeds  
 
Description 
 Trachyspermum ammi is a profusely branched annual herb, 60-90cm tall. Stem is 
striated; inflorescence compound umbel with 16 umblets, each containing upto 16 
flowers; flowers are actinomorphic. Leaves are pinnate, with a terminal and 7 pairs of 
lateral leaflets. Fruit is aromatic, consists of 2 mericarps, grayish brown ovoid, 
compressed about 2mm long and 1.7 mm wide, consists of 5 ridges and 6 vittae in each 
mericarps, usually separate. 
 
Habitat  
 Trachyspermum ammi is widely grown in arid and semi arid regions where soil 
contains high levels of salt. It is a native of Egypt and it is cultivated in Iran, Iraq, 
Pakistan and India. In India, it is cultivated in Madhya Pradesh, Uttar Pradesh, Gujarat, 
Rajasthan, Bihar and West Bengal.  
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Therapeutic uses
 [52, 53, 54] 
 The roots are diuretic in nature.  
 The seeds posses digestive, carminative, laxative properties. It also cures 
abdominal pain and piles. 
 The fruit act as stimulant and antispasmodics. 
 
3.13 Pharmacological investigation 
Antihypertensive, antispasmodic and broncho-dilating activity 
 Gilani AH et al. (2005) reported the antihypertensive effect of T. ammi 
administered intravenously in vivo, and the antispasmodic and broncho-dilating actions 
in vitro showed that calcium channel blockade has been found to mediate the 
spasmolytic effects of plant materials and it is being considered that this mechanism 
contributed to their observed result and supported the traditional use of T. ammi in 
hyperactive disease states of the gut such as colic and diarrhea as well as in 
hypertension.
[55] 
 
Hepatoprotective activity  
 The research work done by Gilani AH et al. (2005) on the  hepatoprotective 
actions in vivo showed that T. ammi was 80% protective in mice against a normally-
lethal dose of paracetamol (1 g/kg), it prevented the CCl4-induced prolongation of 
pentobarbital sleeping time in mice, and it tended to normalize the high serum levels of 
liver enzymes caused by CCl4-induced liver damage in rats.
[55] 
 
Antilithiasis and diuretic activity 
 Ashan SK et al. (1990) reported antilithiasis and diuretic actions in vivo of T. 
ammi on inhibiting oxalate urolithiasis induced in rats were also studied. In a further 
study of a possible diuretic effect, it was found that T. ammi was not effective in 
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increasing the 24-hr urine production. The results concluded that the traditional use of T. 
ammi in the treatment of kidney stones was not supported by their experimental 
evidence.
 [56] 
 
Antiplatelet-aggregatory 
 Srivatsava KC et al. (1988) reported the Antiplatelet-aggregatory experiments in 
vitro with blood from human volunteers and he showed that a dried ethereal extract of T. 
ammi seeds, inhibited aggregation of platelets, induced by arachidonic acid, collagen and 
epinephrine. Research study was intended to support the traditional use of T. ammi in 
women post parturition.
 [57] 
 
Anti-inflammatory potential 
 Thangam C et al. (2003) reported the anti-inflammatory potential of the total 
alcoholic extract (TAE) and total aqueous extract (TAQ) of the T.ammi seeds. TAE and 
TAQ exhibited significant (P<0.001) antiinflammatory activity in both the animal 
models. The weights of the adrenal glands were found to be significantly increased in 
TAE and TAQ treated animals. TAE and TAQ extracts from the T.ammi seeds exhibit 
significant anti-inflammatory potential.
 [58] 
 
Antitussive effects 
 Antitussive effects of aerosols of two different concentrations of aqueous and 
macerated extracts and carvacrol, codeine, and saline were tested by Boskabady MH et 
al.(2005) by counting the number of coughs produced. The results showed significant 
reduction of cough number obtained in the presence of both concentrations of aqueous 
and macerated extracts and codeine (P < 0.001 for extracts and P < 0.01 for codeine).
[59] 
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Detoxification of aflatoxins 
 Vijayanandraj S et al. (2010) after his research on the seed extract of T. ammi, 
showed the maximum degradation of aflatoxin G1 (AFG1). The aflatoxin detoxifying 
activity of the seeds extract was significantly reduced upon boiling. Significant levels of 
degradation of other aflatoxins viz., AFB1, AFB2 and AFG2 by the dialyzed seeds 
extract were also observed. Time course study of AFG1 detoxification by dialyzed T. 
ammi extract showed that more than 91% degradation occurred at 24 h and 78% 
degradation occurred within 6 h after incubation.
[60] 
 
Ameliorative effect 
 Effects of T. ammi extract on hexachlorocyclohexane (HCH)-induced oxidative 
stress and toxicity in rats were investigated by Anilakumar KR et al.(2009).  Pre-feeding 
of ajwain extract resulted in increased GSH, GSH-peroxidase, G-6-PDH, SOD, catalase, 
glutathione S-transferase (GST) activities and decreased hepatic levels of lipid peroxides. 
It was concluded that HCH administration resulted in hepatic free radical stress, causing 
toxicity, which could be reduced by the dietary T. ammi extract.
[61] 
 
Antimicrobial actions in vitro 
 Antimicrobial  actions of T. ammi, in the protection of foodstuffs against 
microbial spoilage, conducting laboratory assays of antimicrobial efficacy in vitro, and 
its use as antimicrobials in humans, were also investigated by Caccioni DLR et al.(2000) 
The active principles thought to be responsible for the antimicrobial activity of T. ammi 
were reported to be carvacol and thymol. ‘Thymol kills the bacteria, resistant to even 
prevalent third generation antibiotics and multi-drug resistant microbial pathogens and 
thus works as a plant based 4th generation herbal antibiotic formulation. Antifungal 
action of volatile constituents of T. ammi seeds on ten fungi (Acrophialophora fusispora, 
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Curvularia lunata, Fusarium chlamydosporum, F. poae, Myrothecium roridum, 
Papulaspora sp., Alternaria grisea, A. tenuissima, Drechslera tetramera,., and 
Rhizoctonia solani) was tested and found to inhibit the growth of all test fungi by 72-
90%. Phenolic compounds, such as thymol and carvacol, are known to be either 
bactericidal or bacteriostatic agents depending on the concentration used.
[62] 
 
Hypolipidemic action in vivo 
 Javed IMS et al. 2002, reported the antihyperlipidemic effect of T. ammi seed in 
albino rabbits. It was assessed that T. ammi powder at a dose rate of 2 g/kg body weight 
and its equivalent methanol extract were extensively effective in lipid lowering action by 
decreased total cholesterol, LDL-cholesterol, triglycerides and total lipids.
[63] 
 
Digestive stimulant actions in vivo and in vitro 
 Platel k et al. (2001) showed that T. ammi would increase the secretion of gastric 
acid and he also proved that the addition of T. ammi to the infusion increased the amount 
of gastric acid. Gastric acid secretion was increased nearly four-fold by T. ammi. In 
experimental rats in vivo, the addition of T. ammi to the diet reduced food transit time 
and also enhanced the activity of digestive enzymes and/or caused a higher secretion of 
bile acids.
[64] 
 
Anthelmintic activity  
 Jabar et al. (2006) reported anthelmintic activity of T. ammi and showed its effect 
against specific helminths, e.g. Ascaris lumbricoides in humans and Haemonchus 
contortus in sheep.
[65]
 Anthelmintic activity of T. ammi was proved to be exerted by 
interference with the energy metabolism of parasites through potentiation of ATPase 
activity and thus loss of energy reserves.
[66, 67]
 The plant has also been reported to 
possess cholinergic activity with peristaltic movements of the gut, thus helping in 
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expulsion of intestinal parasites which might also be a contributory factor to its 
anthelmintic activity.
[68] 
 
Nematicidal activity 
 The nematicidal activity of T.ammi was demonstrated by Kwon I et al. (2006) 
Pine Wilt disease is caused by the pinewood nematode (PWN), Bursaphelenchus 
xylophilus. Nematicidal activity of T.ammi oil (ajwain oil) against PWN may be because 
of the constituents (camphene, pinene, myrcene, limonene, terpinene, terpinen- 4-ol, 
thymol and carvacrol)  .
[69]
 PWN bodies are treated with the muscle activity blockers 
levamisole hydrochloride and morantal tatrate.
[70]
 Amino and hydroxyl groups have been 
hypothesized as target sites of methyl isothiocyanate in nematodes.
[71] 
Some essential oils 
have been reported to interfere with the neuromodulator octopamin
[72]
 or GABA-gated 
chloride channels of insect pests.
[73]
 Thymol and carvacrol are very effective against 
PWN. These studies confirm that the nematicidal activity of ajwain oil is mainly 
attributed to the activity of thymol and carvacrol.
[74]
 Nematicidal activity of ajwain 
essential oils LC50 values was 0.431 mg/ml.
[65] 
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4.  METHODOLOGY 
4.1 PLANT PART USED: 
 The seeds of Trachyspermum ammi were used for extraction which was collected 
in month of July 2013 at Tirunenveli. It was examined and authenticated by Mr. V. 
Chelladurai, officer- Botany (scientist retd.), Central Council for Research in Ayurveda 
& Siddha, Govt. of India. 
 
4.2 EXTRACTION  
 It is defined as separation of medicinally active parts of plant using selective 
solvents through standard procedure. 
 
4.3 SOLVENTS USED: 
 Based on polarity various solvents used such as ethanol, acetone, and water. 
 
4.4 TYPE OF EXTRACTION  
 Hot continuous (soxhlet) extraction method. 
 
4.5  PRINCIPLE 
It is a process of continuous extraction method in which the solvent can be 
circulated through the extractor for several times. The vapours of solvent are taken to the 
condenser and the condensed liquid is returned to the extract for continuous extraction.  
 
4.6 PROCEDURE 
 50 grams of seeds was packed into soxhlet apparatus and was subjected to 
extraction sequentially with 500ml of ethanol, acetone,  and water. The extraction was 
continued until the colour of the solvent in the siphon tube became colourless. 
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 Extraction procedure was carried out in Institute of Pharmacology, Madras 
Medical College, and Chennai. Extracts of acetone and ethanol were subjected to 
evaporation at room temperature till a semisolid mass was obtained. Aqueous extract was 
subjected to lyophilisation with the help of lyophiliser to a semisolid mass. 
 
4.7 PHYTOCHEMICAL ANALYSIS
 [75, 76, 77] 
 The freshly prepared extracts of actone, ethanol and water were subjected to 
phytochemical screening for the presence or absence of active constituents by following 
the methods. 
 
Test for Steroids:  
 Salkowskis test: Crude extract was mixed with 2ml of chloroform. Then 2ml of 
conc. Sulphuric acid was added carefully and shaken gently. Appearance of reddish 
brown colour ring indicated the presence of steroids 
 
Test for Flavanoids: 
 Shinoda test:  Crude extract was treated with 5 ml 95% ethanol, few drops 
concentrated hydrochloric acid and 5 grams magnesium turnings and appearance of pink 
colour indicated the presence of steroids 
 
Lead acetate test: Crude extract was treated with few drops of lead acetate 
solution. Appearance of yellow colour precipitate indicates the presence of flavanoids 
Alkaline reagent test: Crude extract was treated with few drops of sodium 
hydroxide solution. Formation of intense yellow color, which becomes colorless on 
addition of dilute acid, indicates the presence of flavonoids. 
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Test for Proteins:  
Millions test: Crude extract was mixed with 2ml of Millions reagent. Appearance 
of white precipitate which turns red on gentle heating, indicates the presence of proteins 
 
Test for Glycosides:  
 Liebermann’s test: Crude extract was mixed with 2ml of chloroform and 2ml of 
acetic acid. Mixture was cooled in ice and conc. sulphuric acid was added. Colour 
change from violet to blue and then to green indicates the presence of steroidal nucleus 
 
Test for Carbohydrates:  
 Fehling’s test: Crude extract was treated with equal volume of Fehling A and 
Fehling B reagents and mixed together and gently boiled. Appearance of brick red 
precipitate at the bottom of the test tube indicate the presence of reducing sugars 
 
Test for phenols and tannins:  
 Crude extract was mixed with 2ml of 2% solution of ferric chloride. Appearance 
of violet colour indicate the presence of phenolic compounds and tannins. Crude extract 
was dissolved in water and treated with 10% of lead acetate solution, appearance of 
white precipitate indicate the presence of tannins and phenolic compounds.  
 
Test for alkaloids:  
 Crude extract was treated with few drops of dilute hydrochloric acid and filtered. 
The filtrate was tested with various alkaloidal reagents such as, 
 
Mayer’s reagent – Cream precipitate  
Dragendroff’s reagent – Orange brown precipitate 
Wagner’s reagent– Reddish brown precipitate 
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Test for terpenoids: 
 5 ml of each extract was mixed in 2 ml of chloroform. 3 ml of concentrated 
H2SO4 was then added to form a layer. A reddish brown precipitate colouration at the 
inyerface is formed indicates presence of terepenoids.                     
  
4.8 PREPARATION OF MEDIA 
Definition 
 Media is a nutritional supplementation essential for maintenance, growth and 
division of cells in-vitro. 
 
Materials required 
1. Minimum essential medium (MEM) in powder form.  
2. Penicillin (100 IU/ml)  
3. Streptomycin (100 μg/ml)  
4. Phenol red  
5. Amphotericin B  
6. L-glutamine (3%)  
7. Foetal bovine serum (FBS) 10%  
8. Sodium bicarbonate (7.5 %) 
 
Procedure:  
 Powder form of MEM was dissolved in one liter of pre sterilized Millipore 
distilled water, mixed well and closed.  
 The medium was sterilized for 15 minutes at 121°c.  
 856 ml of sterilized MEM was taken in a 1000 ml flask and to it one ml of 
penicillin, streptomycin, phenol red and amphotericin B was added and mixed 
well.  
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 10 ml of 3% L-glutamine, 100 ml of FBS and 30 ml of 7.5% sodium bicarbonate 
was added to make up the volume to 1000 ml.  
 pH was adjusted to 7.2 – 7.4 and the medium was stored for two days at 37°c and 
the pH was checked and transferred to the refrigerator.  
 
4.9 CELL LINES AND CULTURE 
 The Human Breast Cancer cell line, MCF-7 was obtained from Tamil Nadu 
Veterinary College, Chennai 
 
 They were cultured in complete essential growth medium in T25ml cultured 
vented flask and incubated at 37°C in 5% CO2 incubator. After 3 days, about 80-90% 
confluent monolayer (adherent) formation was confirmed by inverted microscope and 
used for study. 
 
4.10 SUB-CULTURING ADHERENT CELLS
 [78] 
Materials Required:  
1. Incubator (37°c, 5% CO2)  
2. Laminar flow hood 
3. Minimum essential medium  
4. TPVG solution (Trypsin 2%, PBS – pH 7.4, Versene/EDTA- 0.2%, 
glucose10%)  
5. Tissue culture treated culture flask  
6. Micropipette  
7. Falcon tubes- conical  
8. Inverted microscope  
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Procedure:  
 The culture flask containing the adherent cells (primary culture) was removed 
from the incubator.  
 The culture flask was transferred aseptically to the bio safety cabinet along with 
minimum essential medium and TPVG solution after confirming its 90% 
confluency with the help of inverted microscope.  
 The primary culture was passaged /sub cultured to required number of culture 
flasks for further study.  
 The cap of the culture flask was opened and with the help of micropipette the 
medium was aspirated from the culture flask and discarded.  
 200μl of TPVG solution was added to the culture flask and rinsed well to remove 
any adhering medium and later the solution was aspirated and discarded.  
 500-1000μl of TPVG solution was again added to the culture flask and the 
solution was spread evenly to cover the entire surface of the culture flask.  
 The flask was then incubated for 5 minutes for detachment of adhered cells from 
the monolayer (cell detachment can be viewed and confirmed under microscope 
after 5 minutes of incubation).  
 After detachment of cells from the monolayer, the culture flask was transferred 
back to the bio safety cabinet. The detached cells were suspended completely in 
the TPVG solution by resuspending it with the help of micropipette.  
 The TPVG solution containing the detached cells were aspirated from the culture 
flask and distributed into 7 new tissue culture treated culture flasks for further 
studies.  
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 5ml of fresh minimum essential medium was added to all 7 culture flask 
containing the TPVG solution with suspended cells, such that it covers the entire 
surface of the flask . 
 
4.11 CYTOTOXICITY STUDY 
MTT ASSAY
[44,79] 
 It is a universally accepted invitro method for screening the drugs having 
cytotoxic activity. It was described by Mosmamm (1983) & Monks (1991). This assay is 
used to determine the IC50 of drugs or extracts. 
 
PRINCIPLE 
 The Tetrazolium salt, 3,-(4,5- dimethyl thiazol-2-yl)-2,5,diphenyl tetrazolium 
bromide is reduced into blue formazan product by the mitochondrial dehydrogenase 
enzyme of live or metabolically active cells. 
 
 The intensity of blue or purple colored formazan produced is directly propotional 
to cell viability. 
 
Materials required 
1. Plant extracts 
Ethanol (1000, 500, 250, 125, 62.5, 31.2, 15.6, 7.8) 
2. Reagents 
DPBS 
TPVG  
MEM 
Trypan blue 
MTT dye(5mg/ml) 
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DMSO(0.1% v/v) 
3. Other materials 
  MTT plate with plate with lid 
  Sterile pipette, tips, glove, mask 
  Aluminium foil 
  Incubator  
  Inverted microscope 
  Falcon tubes 
  Haemocytometer, cover slip. 
 
PROCEDURE 
 Culture flask containing the adherent cells were taken from the incubator and 
checked for its confluency.  
 After confirming the confluency, the adherent monolayer cells were detached to 
form a cell suspension by adding an ml of TPVG solution and incubating it for 5 
minutes.  
 After incubation, the TPVG solution containing cells were aspirated from the 
culture flask and transferred to the falcon tubes and was subjected to 
centrifugation at 10000 rpm for 5 minutes.  
 After centrifugation, supernatant was discarded and 1 ml of medium was added to 
the pellet of cells which have sedimented at the bottom of the tube and was 
resuspended well in the medium with the help of micropipette.  
 10μl of this cell suspension was mixed well with 10μl of tryphan blue. 
Cell counting:  
 After placing the cell suspension along with tryphan blue in haemocytometer, the 
numbers of cells in four corner quadrants were counted.  
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 Numbers of cells in left and right top quadrant were found to be 255 and 241 
respectively. Numbers of cells in left and right bottom quadrant were found to be 
335 and 297 respectively.  
 
   Average no of cells =     225+241+335+297         = 274.5 cells/10µl 
             4 
 
No of cells per ml         = 549× 2×10
4   
cells/ ml
       
 
 549 x 104 cells were present in 1 ml of cell suspension; we need to plate 26 wells 
each with 100 μl containing 10000 cells/well for maintaining triplicate condition 
for control, standard and test extracts.  
 Therefore, 274.5 x 104 cells were present in 1000 μl. 10000 cells were present in 
x μl.  
X =       10000 x 1000         =1.82 µl 
                 549×10
4
   
 
 1.82 μl of cell suspension should be mixed with 98 μl of medium for plating one 
well. In order to plate 26 wells, 47.32 μl of cell suspension was mixed with 2548 
μl of medium to get a concentration of 10000 cells / 100 μl for plating the wells.   
 100 μl of this cell suspension were seeded into 26 wells of 96 well plate, and the 
plate was incubated for 24 hours at 37°c, 5% CO2 for attachment of the cells.  
 After 24 hours the seeded cells in the 96 well plate were treated with serial 
concentration of plant extract and the standard drug 5FU.  
 Plant extracts of ethanol and standard drug were initially dissolved in 0.1% v/v 
DMSO and further diluted in serum free medium to get a desired concentration.  
 100 μl of each plant extract and standard concentration were added to the 96 well 
plates to get a final concentration of 1000 μg/ml, 500 μg/ml, 250 μg/ml, 62.5 
μg/ml, 31.2 μg/ml and 15.6 μg/ml for plant extracts and 1000 μg/ml, 500 μg/ml, 
250 μg/ml, 62.5 μg/ml, 31.2 μg/ml and 15.6 μg/ml for standard drug.  
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 Final volume in each well was 200 μl and the plates were incubated again for 48 
hours.  
 Triplicate was maintained for all concentrations and the medium without 
samples were taken as control. 
 
4.12 Extraction of DNA, RNA and Protein using Genei TRI Solution:  
Extraction of DNA, RNA and Protein from the cells which was treated with IC50 
concentration of Ethanolic extract, IC50 concentration of 5 Fluorouracil and control were 
extracted as per Genei TRI Soln Protocol. Fully grown or 90% confluency reached 3 
subcultured or passaged flask is taken. The medium inside the flask is aspirated and 
decanted while cells adhered to the monolayer was kept intact and the flasks were 
subjected to drug treatment.  
 
 Flask 1 is replaced with the fresh medium without any test or standard drug and 
it served as Control.  
 Flask 2 is treated with IC50 concentration of the effective ethanolic extract 
(IC50)confirmed from MTT Assay)  
 Flask 3 is treated with IC50 concentration of standard 5 fluorouracil (IC50 
confirmed from MTT Assay).  
  
 All the three flasks were incubated for 48 hours at 37°c and 5% CO2. After the 
incubation period, the medium inside the flasks were removed and the adhered cells were 
disturbed by treatment with TPVG solution and the TPVG solution containing the 
suspended cells of three flasks were stored in refrigerator for further processing 
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Extraction of RNA :  
Materials Required:  
1. Chloroform  
2. Isopropyl Alcohol  
3. 75% Ethanol  
4. RNase free water  
 
Steps Involved:  
1. Homogenisation  
2. Phase Separation  
3. RNA Precipitation  
4. RNA Wash  
5. Resuspending RNA  
 
Procedure: 
Homogenisation:  
 Cells were pelleted by centrifugation at 1200 rpm for 5 minutes.  
 The supernatant was decanted and 1 ml of TRI solution was added and mixed by 
repetitive pipetting  
Phase Separation:  
 The samples were incubated for 5 minutes at room temperature (without 
exceeding 30°c) to completely dissociate nucleoprotein complex.  
 0.2 ml of chloroform per 1 ml of TRI Solution was added, mixed thoroughly and 
subjected to incubation at room temperature (without exceeding 30°c) for 2-3 
minutes.  
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 The samples were centrifuged at not more than 12000 rpm for 15 minutes at 2-
8°c and the mixture thus obtained contained a lower phenol chloroform phase, 
interphase and colourless upper aqueous phase.  
 Upper aqueous phase will contain RNA.  
 Volume of aqueous phase obtained was about 60% of volume of TRI Solution 
reagent used for homogenization.  
 
RNA Precipitation:  
 Aqueous phase was transferred to fresh 1.5 ml vial.  
 0.5 ml of isopropanol alcohol per 1 ml of TRI Solution was used for initial 
homogenization.  
 Samples were incubated for 10 minutes at room temperature and were subjected 
to centrifugation at 12000 rpm for 10 minutes at 2-8°c.  
 
RNA Wash:  
 Supernatant was decanted and the RNA precipitated as gel like pellet on the sides 
of 1.5 ml vial.  
 RNA pellet was washed once with 75% ethanol, at least 1ml of 75% ethanol was 
used per ml of TRI Solution reagent used for initial homogenization.  
 Solution was centrifuged at 10000 rpm for 10 minutes at 2-8°c  
 
Resuspending RNA:  
 RNA pellet was air dried and re-suspended in100μl RNase free water by passing 
solution few times through pipette tip gently  
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Extraction of DNA: 
Materials required:  
1. Ethanol (100%)  
2. 75% Ethanol  
3. 0.1 M sodium citrate in 10% ethanol.  
4. 8mM Sodium hydroxide.  
5. Wash Buffer : 0.1 N Sodium citrate in 10% ethanol.  
 
Steps involved:  
1. DNA Precipitation  
2. DNA Wash  
3. Re suspending the DNA pellet.  
 
Procedure : 
DNA Precipitation :  
 0.3 ml of 100% ethanol was added per 1 ml of TRI Solution used for 
homogenization to the inter phase and organic phase which was obtained during 
phase separation in RNA extraction.  
 Samples were stored at room temperature without exceeding 30°c for 2-3 
minutes.  
 Samples were centrifuged at 5000 rpm for 10 minutes at 2-8°c and DNA was 
obtained as a pellet.  
 
DNA Wash:  
 DNA pellet obtained was washed with wash buffer per 1 ml TRI Solution used.  
 After each wash pellet was stored in wash solution for 30 minutes at room 
temperature without exceeding 30°c with periodic mixing.  
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 Samples were centrifuged at 5000 rpm for 10 minutes at 2-8°c and the wash step 
was repeated twice.  
 Following wash, DNA pellet was suspended in 2 ml of 75% ethanol and kept for 
twenty minutes at room temperature and mixed periodically.  
 Samples were centrifuged at 5000 rpm for 10 minutes at 2-8°c.  
 
Re-suspending the DNA Pellet:  
 DNA pellet was air dried for 5-10 minutes.  
 DNA pellet was re-suspended in 300μl to 600μl of 8mM sodium hydroxide so 
that the concentration of DNA was 0.2 - 0.3μg/ml and samples were incubated at 
room temperature for 15-20 minutes  
 
4.13 MICROSCOPIC STUDIES:
[44, 79] 
 Light microscopic study  
Fluorescent microscopic study  
 
Light microscopic studies:  
 Morphological changes in the cancer cells before and after drug treatment can be 
studied with the help of Light microscope.  
 Fully grown or 90% confluency reached subcultured or passaged flask was 
taken.  
 The morphology of the cancer cells in the flask before drug treatment were 
observed under inverted microscope and photographed.  
 The medium inside the flask was aspirated and decanted without disturbing the 
adhered monolayer of cells.  
 The culture flask was then treated with IC50 concentration of effective plant 
extract such that it covers the entire surface area  
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 The flask was then incubated for 48 hours at 5% CO2 and 37°c.  
 After incubation period, the flask was taken and observed under inverted 
microscope and the morphological changes were studied and photographed.  
 The morphological changes of the cancer cells before and after drug treatment 
were evaluated.  
 
Flourescent microscopic studies:  
 Fluorescent microscopy was used to study the viability of cells as well as nuclei 
and chromatin condensation with the help of fluorescent binding dye.  
 Fully grown or 90% confluency reached two subcultured or passaged flask was 
taken.  
 Flask 1 was used for studying the control cancer cells and flask 2 was used for 
studying the extract treated cancer cells.  
 From flask 1 the adhered cells were detached with the help of TPVG solution 
and the TPVG solution containing the cells were centrifuged and the cells were 
pelleted.  
 The pellet of cells were then resuspended in phosphate buffer saline of pH 7.4. 
100 μl of this cell suspension was introduced into microscopic slide along with 
equal mixture of acridine orange and ethidium bromide for staining.  
 The cells were then viewed under fluorescent microscope and the viability and 
nuclear changes were studied and photographed.  
 In flask 2, the medium was aspirated and decanted without disturbing the 
adhered monolayer of cells.  
 Flask was then treated with IC50 concentration of effective plant extract such that 
it covers the entire surface area.  
 The flask was then incubated for 48 hours at 5% CO2 and 37°c.  
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 After incubation period, the flask was taken and the cells were pelleted and the 
same procedure was followed as in flask 1.  
 
4.14 APOPTOTIC DNA FRAGMENTATION
[45,80] 
 Apoptosis is a programmed cell death characterized by cleavage of chromosomal 
DNA into oligonucleosomal fragments. Irregularities in apoptosis have paved way for 
many diseases like cancer, autoimmune disease and neuronal degeneration. Cleavage of 
chromosomal DNA into oligonucleosomal fragments is a hallmark of apoptosis. This 
cleavage of DNA or its fragmentation can be visualized by DNA laddering assay. This 
fragmentation of DNA in cancer cells after treatment with standard drug or test extract 
can be studied with the help of Agarose Gel Electrophoresis. Electrophoresis is a method 
of separating substances based on the rate of movement under the influence of electric 
field. 
 
Materials required:  
 1. Agarose  
2. 5X TAE buffer  
3. 6X loading dye  
4. DNA ladder  
5. Electrophoresis chamber  
6. Gel casting tray and comb  
7. Ethidium bromide  
8. Microwave oven  
9. Conical flask  
10. Sterile tips and pipettes  
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Procedure: 
The steps involved are:  
 Preparation of Agarose gel slab  
 Loading of samples  
 Running the gel  
 
Preparation of Agarose gel slab:  
 Gel casting tray and comb was wiped with ethanol and dried. The two open ends 
of the tray were sealed with tape.  
 Place the combs in the gel casting tray.  
 1.2 grams of agarose powder was weighed and transferred to 500 ml conical 
flask containing 100 ml of TAE buffer.  
 Agarose was melted using microwave oven until the solution became clear.  
 The solution was cooled to about 50 - 55°c by swirling the flask occasionally or 
placing it in water bath.  
 3μl of ethidium bromide was added to the solution and mixed well.  
 The gel casting tray along with comb was kept horizontally on a flat even 
surface.  
 Agarose solution was poured evenly on the casting tray such that it covers the 
entire surface evenly without any bubble formation and was allowed to cool and 
solidify into a gel slab.  
 After solidification, remove the tapes from both ends of the tray and place the 
gel in electrophoresis chamber and add enough TAE buffer so that there is 2-3 
mm of buffer over the gel and carefully pull out the comb out of the tray to form 
wells.  
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Loading of samples:  
 DNA which was extracted from the control, standard and extract treated cancer 
cells was taken. 
 DNA was taken and mixed with required TAE buffer to make a final volume of 
10μl each for a sample.  
 2 μl of 6X loading dye was added to the DNA sample and mixed well.  
 10μl of 100 base pair standard DNA ladder and 12μl of DNA samples were 
loaded carefully in the submerged wells of gel slab in the electrophoresis 
chamber  
 
Running the Gel:  
 Lid was placed on the gel box and the electrodes were connected.  
 Electrode wires were connected to power supply and about 80 volts of current 
were passed.  
 Power supply to the electrophoresis chamber was ensured until the blue dye 
approached the end of the gel.  
 Later power supply was cut off, wires were disconnected and the lid was 
removed.  
 Gel tray was carefully taken out and the gel was placed inside the Gel 
photostation and photographed in presence of UV light  
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4.15 Real time Reverse Transcriptase Polymerase Chain Reaction:
[47]
  
 Real time reverse transcriptase polymerase chain reaction is abbreviated as qRT-
PCR. It is a technique where expression of RNA is studied by converting it into cDNA 
with the help of enzyme reverse transcriptase and quantitatively measuring the amount of 
amplified target sequence from entire cDNA using fluorescent dye SYBR green in real 
time.Upon binding with DNA, SYBR green dye used will emit fluorescence and the 
fluorescence intensity is directly proportional to number of DNA copies or expression 
produced. The fluorescence which is emitted is analysed by detector with the help of 
LED source and it gives the relative expression of genes. The procedure was carried out 
as per Step 1 plus ABI protocol. 
 
Procedure: 
A) Complementary DNA Synthesis: 
Materials Required:  
1. 5X buffer  
2. 10mm dNTPs  
3. Hexamer primer  
4. Extracted RNA  
5. Thermal cycler  
6. Reverse transcriptase  
7. DTT  
 
Procedure:  
 In a 200μl eppendorf tubes, 5μl of 5X buffer, 2μl of 10mm DNTPs and 1.5μl of 
hexamer primer was added.  
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 Later 15μl of extracted RNA was added and the eppendorf tubes were kept in 
thermal cycler at 70°c for 5 minutes to separate the false double stranded RNA.  
 The tubes were taken out and immediately cooled with ice to prevent binding of 
false double stranded RNA again.  
 1.5μl of Reverse transcriptase and 1μl of DTT was added to the tube and spun 
for few seconds.  
 It was then placed in thermal cycler , at 25°c for 5 minutes for binding of 
hexamer, followed by at 42°c for 45 minutes for cDNA synthesis, followed by at 
85°c for 5 minutes for denaturation of remaining unconverted RNA’s and finally 
at 4°c for 5 minutes  
 
B) Primer synthesis: The primers synthesized were P53, Bcl2, TNF α and IL – 6 along 
with house keeping gene GPDH. The primers were synthesized by Geno Rime with 
the help of Primer express software with the available primer sequence. 
The concentration of primers synthesized were 100pM/μl. It was diluted in the ratio 
of 1: 10 with water to get a concentration of 10pM/μl. 
 
C) Real time PCR:  
 The materials required are  
 25μl of SYBR green 
 RT mix 
  5μl of cDNA 
   2μl of 25 pM/μl forward primer 
  2μl of 25 pM/μl reverse primer 
  16μl PCR grade water. 
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 For a total of 50 μl reaction, the above mentioned mixtures were added into 
eppendorf tubes and they were placed in real time PCR instrument and the 
program was set as follows:  
 Step 1: Pre denaturation at 95˚C for 1 minute 
 Step 2: Denaturation at 95˚C for 15 seconds 
 Step 3: Annealing at 60˚C for 15 seconds 
 Step 4: Extension at 72˚C for 45 seconds  
 Step 2 to step 4 repeated for 40 cycles.  
 The relative expression of genes was analyzed and interpreted by Applied 
Biosystem Software.  
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5. RESULTS 
 
TABLE-1 : Phytochemical Analysis 
  
Constituents Ethanolic extract Acetone extract Aqueous extract 
Proteins Absent Present Absent 
Flavanoids Present Absent Absent 
Alkaloids Present Present Absent 
Glycosides Present Present Absent 
Steroids Present Absent Absent 
Carbohydrates Present Present Absent 
Phenols and tannins Present Absent Absent 
Terpenes Present Absent Absent 
 
Phytochemical analysis was carried out for ethanolic, acetone and aqueous extracts 
of seeds of Trachyspermum ammi and the results are shown in the above TABLE-1 
 
 Phyto chemical analysis was performed with ethanol, acetone, aqueous extract of 
Trachyspermum ammi 
 Ethanolic extract showed presence of Flavanoids, Alkaloids, Glycosides, 
Steroids, Carbhohydrates, Phenols, Tannis and Terpenes except Protein. 
 Acetone extract showed presence of Proteins, Glycosides, Carbhohydrates. 
 Aqueous extract did not show presence of any constituents. 
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TABLE-2 : Percentage yield of extracts 

EXTRACT % YIELD
1. Ethanol 4.98 
2. Acetone 2.09 
3. Aqueous 7.05 
 
Percentage yield of various extracts are shown in above TABLE-2 
 
The percentage yield was high in aqueous and low in acetone extract. 
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2. CYTOTOXICITY TEST 
 
TABLE-3  MTT assay of ethanolic extract. 
S.  
No. 
Concentration 
(µg/ml) 
Dilutions 
Absorbance 
(O.D) 
Cell viability 
(%) 
1 1000 Neat 0.09 14.28 
2 500 1:1 0.17 26.98 
3 250 1:2 0.26 41.26 
4 125 1:4 0.32 50.79 
5 62.5 1:8 0.37 58.73 
6 31.2 1:16 0.40 63.49 
7 15.6 1:32 0.43 68.25 
8 7.8 1:64 0.46 73.01 
9 Cell control - 0.63 100 
 
TABLE-3 shows  IC50 concentration and percentage of cell viability of Ethanolic 
extract 
 
MTT assay with extract of Trachyspermum ammi was performed in various concentrations. 
 Cell viability of 50.79% was observed in concentration 0f 125 µ/ml which has 
taken as 50% of inhibition of cells (IC50) 
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 FIGURE- 2.  Shows graphical representation of  
% Cell viability vs conc ( µg/ml) in of Ethanolic extract 
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MTT ASSAY 
 
 
(a) (b) 
 
 
(c) (d) 
 
 
(e) (f) 
 
FIGURE -3  shows the MCF-7 cells treated with various concentration of Ethanolic 
extracts  
a.1000 μg/ml                              c.250 μg/ml                                             e.62.5 μg/ml 
b.500 μg/ml                               d.125 μg/ml                                             f.31.2 μg/ml. 
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TABLE -4 MTT Assay of 5 Fluorouracil 
S.No 
Concentration 
(µg/ml) 
Dilutions 
Absorbance Cell viability 
(%) 
(O.D) 
1 1000 Neat 0.01 1.85185185 
2 500 1:01 0.03 5.55555556 
3 250 1:02 0.06 11.1111111 
4 125 1:04 0.1 18.5185185 
5 62.5 1:08 0.13 24.0740741 
6 31.2 1:16 0.17 31.4814815 
7 15.6 1:32 0.2 37.037037 
8 7.8 1 64 0.28 51.8518519 
9 Cell control - 0.54 100 
 
TABLE-4 IC50 concentration and % cell viability of 5 Fluorouracil 
 
Cell viability of 51.85 % was observed in concentration of 7.8 µg/ml which has taken as 
50% of inhibition of cells (IC50). 
FIGURE-4 
 
FIGURE-4 is a graphical representation of % Cell viability vs  
Concentration in μg/ml 5- Fluorouracil 
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3. Apoptotic activity of ethanolic extracts of Trachyspermum ammi. 
 
Microscopic Studies: 
Light microscopic observation:  
 There was no destruction of cells and cell morphology was well maintained in the 
control group. (FIGURE-5), but the cells treated with with IC50 concentration of 
ethanolic extract of T.ammi showed- 
 
 Reduction and detachment of dead cells 
 Loss of integrity of the membrane resulting in crooked and vesicle shape of the 
membrane 
 Reduction in cell volume 
  Cell shrinkage and chromatin condensation (FIGURE-6) 
 
 
Flourescence microscopic observation:  
 Control cells were bright green in colour. (FIGURE-7) 
 Cells treated with ethanolic extract of Trachyspermum ammi were bright orange 
in colour with loss of membrane integrity and cytoplasmic contents leaking out of 
the cell. (FIGURE-8) 
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Light Microscopic study images 
A) MCF-7 cells – Control 
 
 
FIGURE-5 shows control cell lines with normal morphology. 
 
 
 
B) MCF-7 cells after treatment with ethanolic extract of Trachyspermum ammi 
 
FIGURE-6 shows decrease in cell population, chromatin condensation and 
destruction of cells. 
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Flourescent Microscopic Images 
 
A) MCF-7 cells – Control 
 
FIGURE -7 shows viable cells stained green in colour 
 
 
 
 
B) MCF-7 cells after treatment with Ethanolic extract of Trachyspermum ammi 
 
FIGURE-8 shows dead cells stained orange in colour with loss of membrane 
integrity and cytoplasmic contents leaking out of the cell. 
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DNA Fragmentation: (Agarose Gel Electrophoresis) 
 Control MCF-7 cells, there was no fragmentation. 
 MCF-7 cells treated with IC50 concentration of standard 5 fluorouracil and 
ethanolic extract of Trachyspermum ammi fragmentation was observed 
 This fragmentation of DNA in ethanolic extract treated cells indicates the 
characteristics of apoptotic cells.  
 Results obtained in fragmentation studies are shown in FIGURE -9 
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Agarose Gel Electrophoresis 
                                               1                2                3               4 
                                                                                                   
 
 
FIGURE 9. DNA Fragmentation in MCF-7 
 
Lane 1: 100 base pair DNA marker  
Lane 2: MCF-7 cells treated with 5 Fluorouracil  
Lane 3: MCF-7 cells treated with ethanoic extract of Trachyspermum ammi 
Lane 4: MCF-7 cells without any treatment. 
58 
 
 
4. Real time PCR: 
 The expression levels of p53, Bcl-2 were studied using RT-PCR and the results 
are shown in Table 6 & 7 and figures 10, 11,12 & 13. 
                                  P53 Gene in MCF-7 Cell Line   
                                  M       1         2          3      
 
FIGURE 10. P53 gene expression 
 
M- Marker- 1 kb DNA Ladder. 
Lane 1: Standard 
Lane 2: Sample 
Lane 3 : Control. 
 
  
P53-600bp 
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TABLE-5 QUANTIFICATION OF p53 
 
 
 
 
 
TABLE-5 shows expression levels of p53 
 
 
 On comparing with control both standard 5 fluorouracil and ethanolic extract of 
Trachyspermum ammi expression levels of p53 was higher. 
 Expression levels of p53 was observed to be maximum with standard 5 
fluorouracil(6.45) followed by ethanolic extract of Trachyspermum ammi (4.5). 
 
 
  
 
RELATIVE 
QUATIFICATION 
STANDARD 
ERROR 
CONTROL 2.06 0.1 
5-FU 6.45 0.12 
TEST 4.5 0.11 
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FIGURE- 11 Graphical representation of levels of p53 
 
 
 
 
 
 
 
FIGURE- 11 shows expression levels of p53  
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                                      BCl2 Gene in MCF-7 Cell Line                                         
 
1                  2             3          M 
      
FIGURE 12. Bcl2 gene expression 
. 
Lane 1: Sample 
Lane 2: Sample  
M- Marker- 100 bp DNA Ladder 
 
 
 
  
BCl2- 300bp 
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TABLE-6 Quantification of Bcl2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE-6 shows expression levels of Bcl2 
 
 
 
 On comparing with control both standard 5 fluorouracil and ethanolic extract of 
Trachyspermum ammi expression levels of Bcl2 was lower. 
 Expression levels of Bcl2 was observed to be maximum with of standard 5 
fluorouracil(2.97) followed by ethanolic extract of Trachyspermum ammi (2.47). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
RELATIVE 
EXPRESSION 
STANDARD 
ERROR 
CONTROL 5.21 0.123 
5-FU 2.97 0.09 
TEST 2.47 0.106 
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FIGURE- 13 Graphical representation of levels of Bcl2 
 
 
  
 
 
 
Figure -13 shows relative expression of Bcl2 
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6. DISCUSSION 
 Breast cancer is malignant neoplasm occurring in females. It accounts for 23% 
of newly occurring cancer worldwide and represents 13.7% of all cancer deaths. In both 
developed and developing countries, breast cancer mortality and incidence rates are 
projected to rising continuously. 
 
 In spite of advancing different types of treatments, the rate of breast cancer has 
not decreased yet. The report, by NCEPOD has shown that more than 1 in 4 patients died 
from the side effect rather than from cancer and patients are suffering from treatment 
related toxicity. Because of dangerous side effects and high cost of chemotherapy, usage 
of herbal medicine is on increased in large number of population. 
 
 In search of new compound to treat breast cancer with fewer side effects, 
researchers have been evaluating number of medicinal plants. Since the medicinal plants 
have phyto constituents, which protects the plant from oxidative damages and the same 
phytoconstituents which when used in humans may have the same role. They have wide 
range of action such as antitumor, antiviral, antibacterial, antimutagenic etc and they may 
act in different stage of malignant tumor by protecting the DNA from oxidative damages. 
They inactivate carcinogen by inhibiting the expression of mutagenic genes; they also 
inactivate the enzymes with activate the systems responsible for the detoxification of 
xenobiotics (Bravo, 1998).
[81] 
  
  Trachyspermum ammi has been reported to show a number of biological 
activities in traditional medicine and it has been used as digestive, carminative, laxative, 
diuretic, stimulant and antispasmodics. Several investigation in the seeds of 
Trachyspermum ammi have been indicated to posses many activities like potent 
antibacterial, antimicrobial, anthelmintics, hypolipidemic, etc.  
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Phyto Chemical Analysis 
 The phyto chemical analysis of ethanolic extract of seeds of T. ammi revealed the 
presence of flavanoids, terepenoids, tannis, alkaloids, steroids, glycosides, 
carbhohydrates. The acetone and aqueous extracts didn’t show the presence of flavanoid 
and terepenoids. The ethanolic extract revealed the presence of flavanoids and 
terepenoids which shows that it may  posses anticancer activity and destroy cancer cells. 
[82] 
 
MTT Assay 
 The MTT assay was carried out to determine the IC50 concentration of ethanolic 
extract of Trachyspermum ammi.The effective IC50 of ethanolic extract  was found to be           
125 µg/ml.  
 
 The effective IC50 concentration of ethanolic extract of Trachyspermum ammi 
and standard 5-fluorouracil was chosen for further studies.  
 
Light Microscopy 
 Control did not show apoptosis, but cells treated with of ethanolic extract of 
Trachyspermum ammi showed typical morphological features of apoptosis like 
destruction of cells, reduction of MCF-7 cell population, reduction of cell volume, loss 
of integrity of membrane which resulted in crooked and vesicle shape of the membrane 
and chromatin condensation. 
 
Fluorescence Microscopy 
 Apoptotic effects of IC50 concentration of ethanolic extract of Trachyspermum 
ammi treated MCF-7 cells were further confirmed with the help of fluorescence 
microscopy. Control did not reveal any apoptotic activity. Cells treated with of ethanolic 
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extract of Trachyspermum ammi showed apoptotic activity. The presence of apoptotic 
activity shows ethanolic extract of Trachyspermum ammi may have anticancer activity. 
 
 On comparing with control group, both 5 Fluorouracil and ethanolic extract of 
Trachyspermum ammi has produced DNA fragmentation in MCF-7 cells. The 
fragmentation of DNA indicates that apoptotis has occured. This shows ethanolic extract 
of Trachyspermum ammi posses apoptotic activity. 
 
Gene Expression 
 Cells treated with 5 Fluorouracil, expression levels of p53 was found to be 
increased and similar increase was observed in cells treated with ethanolic extract of 
Trachyspermum ammi. 
 
Expression levels of Bcl-2 were decreased in cells treated with 5 Fluorouracil. 
Cells treated with ethanolic extract of Trachyspermum ammi shows a decrease in 
expression levels of Bcl-2 slightly lower than 5 Fluorouracil. 
 
 Expression levels of p53 and Bcl-2 indicated that ethanolic extract of 
Trachyspermum ammi has anticancer activity. 
 
  
67 
 
 
 
7. CONCLUSION 
 
From the present study it may be concluded that, 
 The phyto chemical investigation revealed the presence of flavanoids, tannins, 
trepenoids, steroids, glycosides, alkaloids. 
 By MTT assay, The IC50 value of ethanolic extract of Trachyspermum ammi was 
found to be 125µg/ml. 
 The ethanolic extract of Trachyspermum ammi posses apoptotic activity. 
 The gene expression of cancer DNA markers in MCF-7 Cell line treated with 
ethanolic extracts of Trachyspermum ammi showed increase in p53 expression 
and decrease in Bcl2 expression. 
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